The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment

Mart oude Egbrink; Maarten IJzerman

doi:10.3402/jmahp.v2.22761

You are currently viewing a new version of our website. To view the old version click .

Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.

Communication

1 April 2014

The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment

and

Department Health Technology and Services Research, School of Management and Governance, University of Twente, NL-7500 Enschede, The Netherlands

Author to whom correspondence should be addressed.

J. Mark. Access Health Policy2014, 2(1), 22761;https://doi.org/10.3402/jmahp.v2.22761

Version Notes

Order Reprints

Abstract

Quantitative patient preferences are a method to involve patients in regulatory benefit-risk assessment. Assuming preferences can be elicited, there might be multiple advantages to their use. Legal, methodological and procedural issues do however imply that preferences are currently at most part of the solution on how to best involve patients in regulatory decision making. Progress is recently made on these issues.

Keywords:

patient involvement; preferences; benefit-risk assessment; European Medicines Agency

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

And If the Discovery of New Drugs for the Treatment of Brain Diseases Depends on Asian Countries?

Pricing and Reimbursement of Novel Oncology Drugs in Sweden